德琪醫藥－Ｂ
Zhongshan SOHO Plaza
Suites 1206-1209 Block B, 1065 West Zhongshan Road Changning District
Shanghai
China
86 21 2356 6665
https://www.antengene.com
版塊: Healthcare
行業: Biotechnology
全職員工: 201
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Jay Mei M.D., Ph.D. | Founder, Chairman & CEO | 10.26M | 無 | 1965 |
| Mr. Donald Andrew Lung J.D., M.B.A. | CFO & Executive Director | 4.19M | 無 | 1982 |
| Mr. John F. Chin M.B.A. | Executive Director & Chief Business Officer | 3.78M | 無 | 1967 |
| Mr. Eitan Liu M.Sc. | Chief Operating Officer | 無 | 無 | 1985 |
| Ms. Kathryn J. Gregory MBA | VP & Head of Corporate Business Development | 無 | 無 | 1962 |
| Ms. Shimin Sun M.D., M.P.H. | Corporate VP and Head of Clinical Enabling Functions & Operational Excellence | 無 | 無 | 無 |
| Mr. Thomas Karalis B.Sc. | Corporate VP & Head of Asia Pacific Region | 無 | 無 | 無 |
| Dr. Dirk Hoenemann | VP and Head of Medical Affairs for APAC & Early Clinical Development | 無 | 無 | 無 |
| Dr. Xiaojing Zhang | Chief Medical Officer | 無 | 無 | 1977 |
| Mr. Yang Cao | Joint Company Secretary | 無 | 無 | 無 |
描述
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. The company also develops other clinical stage assets, such as ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with patients with high-risk myelodysplastic syndromes; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma; ATG-037, an CD73 inhibitor for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; and ATG-031 an anti-CD24 monoclonal antibody. In addition, its pre-clinical stage assets consist of ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Antengene Corporation Limited was founded in 2016 and is headquartered in Shanghai, China.
公司管治
截至 無 止，德琪醫藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
